208 research outputs found
Novel antibodies against RCD-8 as a tool to study processing bodies
Aim. To develop the model system for processing bodies (PBs) state monitoring and accomplish it in the future as a possible read-out of mTOR activity in mammalian cells. Methods. In course of this study we raised polyclonal antibodies against one of the PBs scaffold proteins β RCD-8 and employed cell imaging technique. Results. It has been shown that the obtained antibodies recognize the intracellular structures, namely PBs. The detected protein co-localized with known marker of PBs β DCP1a, and partly with marker of SGs β CPEB. Conclusions. Based on changes of PBs number and size in cells after exposure to known inductors or inhibitors of PB formation we prove the specificity of generated antibodies and possibility of their application for studies on the processing bodies dynamics controlled by mTOR-dependent signalin
Π§Π΅ΡΠ²Π΅ΡΡΠ° ΠΌΡΠΆΠ½Π°ΡΠΎΠ΄Π½Π° Π½Π°ΡΠΊΠΎΠ²Π°-ΠΏΡΠ°ΠΊΡΠΈΡΠ½Π° ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΡΡ Β«ΠΠΎΠΌΠΏβΡΡΠ΅ΡΠ½Π΅ ΠΌΠΎΠ΄Π΅Π»ΡΠ²Π°Π½Π½Ρ Π² Ρ ΡΠΌΡΡ Ρ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΡΡΡ ΡΠ° ΡΠΈΡΡΠ΅ΠΌΠ°Ρ ΡΡΠ°Π»ΠΎΠ³ΠΎ ΡΠΎΠ·Π²ΠΈΡΠΊΡΒ»
ΠΠ΄Π΅ΡΠΆΠ°Π½ΠΎ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ½ΠΈΠΉ ΠΎΠΏΠΈΡ ΡΠ΅Π°ΠΊΡΠΎΡΠ°-Π·ΠΌΡΡΡΠ²Π°ΡΠ° Π²ΡΠ΄Π΄ΡΠ»Π΅Π½Π½Ρ Π΄ΠΈΡΡΠΈΠ»ΡΡΡΡ
Π²ΠΈΡΠΎΠ±Π½ΠΈΡΡΠ²Π° ΡΠΎΠ΄ΠΈ. ΠΠ°Π²ΠΎΠ΄ΡΡΡΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΈ ΡΠΈΡΠ»ΠΎΠ²ΠΈΡ
Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ ΡΠΎΠ·ΠΊΠ»Π°Π΄Π°Π½Π½Ρ Ρ
Π»ΠΎΡΠΈΡΡΠΎΠ³ΠΎ
Π°ΠΌΠΎΠ½ΡΡ Π³ΡΠ΄ΡΠΎΠΎΠΊΠΈΡΠΎΠΌ ΠΊΠ°Π»ΡΡΡΡ. ΠΡ
Π°Π½Π°Π»ΡΠ· Π΄ΠΎΠ·Π²ΠΎΠ»ΠΈΠ² Π²ΠΈΠ·Π½Π°ΡΠ°ΡΠΈ Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΡΠΎΠ±ΠΎΡΠΈ ΡΠ΅Π°ΠΊΡΡΠΉΠ½ΠΎΡ
Π·ΠΎΠ½ΠΈ ΡΠ΅Π°ΠΊΡΠΎΡΠ°.Mathematical description of reactor-mixer of of soda production distillation department
been obtained. Results over of computational simulation researches of decomposition of ammonium
chloride by the hydroxide of calcium are represented. The fnflysis allowed determining efficiency of
work of reactionary zone in reactor.ΠΠΎΠ»ΡΡΠ΅Π½ΠΎ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΡΠ΅Π°ΠΊΡΠΎΡΠ°-ΡΠΌΠ΅ΡΠΈΡΠ΅Π»Ρ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π΄ΠΈΡΡΠΈΠ»Π»ΡΡΠΈΠΈ
ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° ΡΠΎΠ΄Ρ. ΠΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΈΡΠ»Π΅Π½Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ°Π·Π»ΠΎΠΆΠ΅Π½ΠΈΡ
Ρ
Π»ΠΎΡΠΈΡΡΠΎΠ³ΠΎ Π°ΠΌΠΌΠΎΠ½ΠΈΡ Π³ΠΈΠ΄ΡΠΎΠΎΠΊΠΈΡΡΡ ΠΊΠ°Π»ΡΡΠΈΡ. ΠΡ
Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ
ΡΠ°Π±ΠΎΡΡ ΡΠ΅Π°ΠΊΡΠΈΠΎΠ½Π½ΠΎΠΉ Π·ΠΎΠ½Ρ ΡΠ΅Π°ΠΊΡΠΎΡΠ°
Study of application of hydrophobic fibrous sorbents for water purification from metal ions
Sorption properties of hydrophobic fibrous sorbents on the basis of polypropylene and polyethylene terephthalate produced from thermoplastic polymer wastes to metal ion series in aqueous media has been studied. Based on the experimental data of extraction degree dependencies on fibre laying density, dispersity, presence of air in sorbent, volume of pass solution the mechanism of metal ion sorption from aqueous media with hydrophobic fibrous materials is suggested
IGHV3-21 gene expression in patients with b-cell chronic lymphocytic leukemia in Ukraine
The aim of the study was to evaluate the frequency of IGHV3-21 gene usage and its clinical significance for patients with B-cell chronic lymphocytic leukemia (CLL) in Ukraine. Patients and Methods: Immunoglobulin variable heavy chain (IGHV) gene repertoire was studied in 189 CLL patients using reverse transcribed polymerase chain reaction and direct sequence of amplified products. Results: IGHV3-21 gene expression was found in 11 cases (5.8%), and its frequency was intermediate between Scandinavian (11.7%) and Mediterranean CLL (2.9%) cohorts. The most of cases (9 of 11) belonged to subset with heterogeneous HCDR3 (heteroHCDR3 subset), and only 2 cases β to subset with classical short ARDANGMDV motif (homHCDR3 subset). Six IGHV3-21 cases were mutated and 5 cases were unmutated. All unmutated cases (all were from heteroHCDR3 subset) had similarity of their HCDR3s with previously published sequences. The differences in overall (OS), progression-free (PFS) and treatment-free survival (TFS) for IGHV3-21 positive patients in comparison with CLL patients expressing the other IGHV genes were statistically insignificant. These survival parameters were comparable also for CLL patients with mutated IGHV3-21 gene usage and expression the others mutated IGHV genes. But remarkable feature of IGHV3-21 expressing patients was high incidence of solid tumors. They have developed in 4 IGHV3-21 positive cases (36.4%) and in 10 cases with expression of the others IGHV genes (5.6%, p = 0.0002). Furthermore, in small group of 6 patients with mutated IGHV3-21 gene expression, 3 patients had solid tumors and one underwent Richter transformation. Unmutated IGHV3-21 gene expressed patients had worse OS and PFS in comparison with CLL patients that expressed the others unmutated IGHV genes. Conclusion: Presented data are in agrement with the opinion about negative prognostic significance of IGHV3-21 gene expression regardless its mutation status. IGHV3-21 expression was associated with development of secondary solid tumors. Revealed high level of homology in heteroHDR3s subset might suggest about possible antigenic influence also, in addition to homHCDR3 subset that was proposed earlier.Π¦Π΅Π»Ρ: ΠΎΡΠ΅Π½ΠΈΡΡ ΡΠ°ΡΡΠΎΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π³Π΅Π½Π° IGHV3-21 ΠΈ Π΅Π³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
B-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ
Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ (Π₯ΠΠ) Π² Π£ΠΊΡΠ°ΠΈΠ½Π΅. ΠΠΎΠ»ΡΠ½ΡΠ΅ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΡΠ΅ΠΏΠ΅ΡΡΡΠ°Ρ Π³Π΅Π½ΠΎΠ² Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΡΡ
ΡΡΠ°ΡΡΠΊΠΎΠ² ΡΡΠΆΠ΅Π»ΡΡ
ΡΠ΅ΠΏΠ΅ΠΉ
ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ΠΎΠ² (IGHV) ΠΈΠ·ΡΡΠ°Π»ΠΈ Ρ 189 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π₯ΠΠ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π½Π° Π±Π°Π·Π΅ ΠΎΠ±ΡΠ°ΡΠ½ΠΎΠΉ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΈ
ΠΈ ΠΏΡΡΠΌΠΎΠ³ΠΎ ΡΠΈΠΊΠ²Π΅Π½ΡΠ° Π°ΠΌΠΏΠ»ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ². Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π΅Π½Π° IGHV3-21 Π²ΡΡΠ²Π»Π΅Π½Π° Ρ 11 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (5,8%),
ΡΡΠΎ Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΎΡΠ½ΠΎΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΌΠ΅ΠΆΠ΄Ρ Π‘ΠΊΠ°Π½Π΄ΠΈΠ½Π°Π²ΡΠΊΠΎΠΉ (11,7%) ΠΈ Π‘ΡΠ΅Π΄ΠΈΠ·Π΅ΠΌΠ½ΠΎΠΌΠΎΡΡΠΊΠΎΠΉ (2,9%) ΠΊΠΎΠ³ΠΎΡΡΠ°ΠΌΠΈ. ΠΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ
ΡΠ»ΡΡΠ°Π΅Π² (9 ΠΈΠ· 11) ΠΎΡΠ½ΠΎΡΠΈΠ»ΠΈΡΡ ΠΊ ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ΅ Ρ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΡΠΌ ΡΡΠ΅ΡΡΠΈΠΌ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ°ΡΠ½ΡΠΌΡΠ΅Π³ΠΈΠΎΠ½ΠΎΠΌ (heteroHCDR3 ΠΏΠΎΠ΄Π³ΡΠΏΠΏΠ°) ΠΈ ΡΠΎΠ»ΡΠΊΠΎ
2 ΡΠ»ΡΡΠ°Ρ β ΠΊ ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ΅ Ρ ΠΊΠΎΡΠΎΡΠΊΠΈΠΌ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ARDANGMDV ΠΌΠΎΡΠΈΠ²ΠΎΠΌ (homHCDR ΡΠΏΠΏΠ°). Π΅ΡΡΡ IGHV3-21-ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
ΡΠ»ΡΡΠ°Π΅Π² Π±ΡΠ»ΠΈ ΠΌΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΠΈ 5 β Π½Π΅ΠΌΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ. ΠΡΠ΅ Π½Π΅ΠΌΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΡΠ»ΡΡΠ°ΠΈ (Π²ΡΠ΅ ΠΈΠ· heteroHCDR ΡΠΏΠΏΡ)
ΠΈΠΌΠ΅Π»ΠΈ ΡΡ
ΠΎΠ΄ΡΡΠ²ΠΎ HCDR3 Ρ Π°Π½Π΅Π΅ ΠΎΠΏΠΈΡΠ°Π½Π½ΡΠΌΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΡΠΌΠΈ. Π Π°Π·Π»ΠΈΡΠΈΡ Π² ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ (OS), Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ
ΠΏΠ΅ΡΠΈΠΎΠ΄Π° Π΄ΠΎ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (PFS) ΠΈ Π½Π°ΡΠ°Π»Π° Π»Π΅ΡΠ΅Π½ΠΈΡ (TFS) Π΄Π»Ρ IGHV3-21-ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Π±ΡΠ»ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ
Π½Π΅Π·Π½Π°ΡΠΈΠΌΡ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Ρ Π₯ΠΠ Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ Π΄ΡΡΠ³ΠΈΡ
IGHV-Π³Π΅Π½ΠΎΠ². Π£ΠΊΠ°Π·Π°Π½Π½ΡΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ ΡΠ°ΠΊΠΆΠ΅ ΡΡΠ°Π²Π½ΠΈΠ²Π°Π»ΠΈ
ΠΌΠ΅ΠΆΠ΄Ρ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Π₯ΠΠ Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ ΠΌΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
IGHV3-21- ΠΈ Π΄ΡΡΠ³ΠΈΡ
IGHV-Π³Π΅Π½ΠΎΠ². ΠΡΠ»ΠΈΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΡΠΎΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ
ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ IGHV3-Π³Π΅Π½Π° Π±ΡΠ»Π° Π²ΡΡΠΎΠΊΠ°Ρ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΡ ΡΠΎΠ»ΠΈΠ΄Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ. ΠΠ½ΠΈ ΡΠ°Π·Π²ΠΈΠ»ΠΈΡΡ Π² 4 IGHV3-21-ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
ΡΠ»ΡΡΠ°ΡΡ
(36,4%) ΠΈ Π² 10 ΡΠ»ΡΡΠ°ΡΡ
Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ Π΄ΡΡΠ³ΠΈΡ
IGHV-Π³Π΅Π½ΠΎΠ² (5,6%, p = 0,0002). ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, Π² Π½Π΅Π±ΠΎΠ»ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
(6) Ρ
ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ ΠΌΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ IGHV3-21-Π³Π΅Π½Π° Ρ 3 Π²ΠΎΠ·Π½ΠΈΠΊΠ»ΠΈ ΡΠΎΠ»ΠΈΠ΄Π½ΡΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ 1 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° β ΡΠΈΠ½Π΄ΡΠΎΠΌ Π ΠΈΡ
ΡΠ΅ΡΠ°. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ
ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ Π½Π΅ΠΌΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ IGHV3-21-Π³Π΅Π½Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Ρ
ΡΠ΄ΡΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ OS ΠΈ PFS ΠΏΠΎ ΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ
Π΄ΡΡΠ³ΠΈΡ
Π½Π΅ΠΌΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
IGHV-Π³Π΅Π½ΠΎΠ². ΠΡΠ²ΠΎΠ΄Ρ: ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠΎΠ³Π»Π°ΡΡΡΡΡΡ Ρ ΠΌΠ½Π΅Π½ΠΈΠ΅ΠΌ ΠΎ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎΠΌ
Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΎΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΌ Π·Π½Π°ΡΠ΅Π½ΠΈΠΈ Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π₯ΠΠ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ IGHV3-21-Π³Π΅Π½Π° Π²Π½Π΅ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π΅Π³ΠΎ ΠΌΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ
ΡΡΠ°ΡΡΡΠ°. IGHV3-21-ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π±ΡΠ»Π° Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ Π²ΡΠΎΡΠΈΡΠ½ΡΡ
ΡΠΎΠ»ΠΈΠ΄Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ. ΠΡΡΠ²Π»Π΅Π½Π½ΡΠΉ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ
Π³ΠΎΠΌΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² heteroHDR3s-ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ΅ ΠΌΠΎΠΆΠ΅Ρ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΌ Π°Π½ΡΠΈΠ³Π΅Π½Π½ΠΎΠΌ Π²Π»ΠΈΡΠ½ΠΈΠΈ Π² Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΠΊ Π°Π½ΡΠΈΠ³Π΅Π½Π½ΠΎΠΌΡ
Π²Π»ΠΈΡΠ½ΠΈΡ Π² homHCDR ΡΠΏΠΏΠ΅, ΡΡΠΎ Π±ΡΠ»ΠΎ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ ΡΠ°Π½Π΅
ΠΠΠ«Π’ ΠΠ ΠΠΠΠΠΠΠΠ― ΠΠ ΠΠΠ£ΠΠΠΠ Π Π£Π‘ΠΠΠΠΠ―Π₯ Π ΠΠΠΠ¬ΠΠΠ ΠΠΠΠΠΠ§ΠΠ‘ΠΠΠ ΠΠ ΠΠΠ’ΠΠΠ
Background: Eribulin mesylate was initially approved in 2010 by FDA as a third-line treatment for women with advanced breast cancer (ABC) pretreated with at least two lines of chemotherapy, and then in 2011 it was approved by EMA as a second-line therapy. Patients should have received an anthracycline and a taxane in either the adjuvant or metastatic setting. Since then, several studies have been conducted confirming its efficacy and safety. We report our experience of using eribulin in our centre in a real-life clinical setting.Materials and methods: 34 patients with ABC were enrolled to receive eribulin. From February 2016 to February 2017, patients were treated with standard doses of eribulin and evaluated for toxicity and responses. All of them had previously received anthracyclines and taxanes in either the adjuvant or metastatic setting. Median age was 60 years (range: 39β79). ECOG performance status was 1 or 2 at the time of enrollment. Median number of cycles of eribulin was 5 (range 2β10). Patients received eribulin from first-line chemotherapy to seventh-line chemotherapy for ABC. Median number of envolved visceral organs was 2 (range 1β4).Results: There were no complete responses. Partial responses were achieved in 26.4% (9/34), stabilization of the disease in 32.4% (11/34) and progression of the disease in 41.2% (14/34) of patients. The median progression-free survival was 4.09 months (range: 2.6β6.53). Main toxicities (grade 3β4) included peripheral neuropathy and neutropenia. Neuropathy was marked in 14.7% (5/34) and neutropenia in 14.7% (5/34) of patients. Dose reductions were required in 14.7% (5/34) of patients because of neutropenia.Conclusion: Our experience shows that eribulin has clinical activity as well as satisfactory tolerability in unselected patients in a reallife clinical setting. Thus, in our opinion, eribulin can represent a new option in treatment of ABC patients.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅: ΠΡΠΈΠ±ΡΠ»ΠΈΠ½ Π²ΠΏΠ΅ΡΠ²ΡΠ΅ Π±ΡΠ» Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ FDA Π² 2010 Π³. Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ 3 Π»ΠΈΠ½ΠΈΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ (ΠΌΠ ΠΠ), ΡΠ°Π½Π΅Π΅ ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΡ
ΠΏΠΎ ΠΊΡΠ°ΠΉΠ½Π΅ΠΉ ΠΌΠ΅ΡΠ΅ 2 Π»ΠΈΠ½ΠΈΠΈ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°, Π²ΠΊΠ»ΡΡΠ°Π²ΡΠΈΠ΅ Π°Π½ΡΡΠ°ΡΠΈΠΊΠ»ΠΈΠ½Ρ ΠΈ ΡΠ°ΠΊΡΠ°Π½Ρ. ΠΠ°Π»Π΅Π΅ Π² 2011 Π³. EMA ΠΎΠ΄ΠΎΠ±ΡΠΈΠ»Π° ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ 2 Π»ΠΈΠ½ΠΈΠΈ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Π΄ΠΎΠ»ΠΆΠ½Ρ Π±ΡΠ»ΠΈ ΠΏΠΎΠ»ΡΡΠ°ΡΡ Π°Π½ΡΡΠ°ΡΠΈΠΊΠ»ΠΈΠ½Ρ ΠΈ ΡΠ°ΠΊΡΠ°Π½Ρ ΠΈΠ»ΠΈ Π² Π°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠΌ, ΠΈΠ»ΠΈ Π»Π΅ΡΠ΅Π±Π½ΠΎΠΌ ΡΠ΅ΠΆΠΈΠΌΠ΅. Π Π½Π°ΡΡΠΎΡΡΠ΅ΠΌΡ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½ ΡΡΠ΄ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°ΡΡΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°. Π Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΎΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½Π° Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ.ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Π‘ ΡΠ΅Π²ΡΠ°Π»Ρ 2016 ΠΏΠΎ ΡΠ΅Π²ΡΠ°Π»Ρ 2017 Π³. Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ΠΎΠΌ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ 34 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠΈΠΌ ΠΌΠ ΠΠ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅ΠΉ ΠΎΡΠ΅Π½ΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°. ΠΡΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π°Π½ΡΡΠ°ΡΠΈΠΊΠ»ΠΈΠ½ΠΎΠ² ΠΈ ΡΠ°ΠΊΡΠ°Π½ΠΎΠ² ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΌΠ΅ΡΡΠ½ΠΎΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈ/ΠΈΠ»ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΠΊΠ°. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ» 60 Π»Π΅Ρ (ΠΎΡ 39 Π΄ΠΎ 79 Π»Π΅Ρ). Π‘ΡΠ°ΡΡΡ ΠΎΠ±ΡΠ΅Π³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ ECOG Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Π±ΡΠ» ΠΎΡ 0 Π΄ΠΎ 2. ΠΠ΅Π΄ΠΈΠ°Π½Π° ΡΠΈΡΠ»Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΡ
ΠΊΡΡΡΠΎΠ² Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ΠΎΠΌ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 5 (ΠΎΡ 2 Π΄ΠΎ 10 ΠΊΡΡΡΠΎΠ²). ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ Ρ ΠΏΠ΅ΡΠ²ΠΎΠΉ ΠΏΠΎ ΡΠ΅Π΄ΡΠΌΡΡ Π»ΠΈΠ½ΠΈΠΈ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΌΠ ΠΠ. Π‘ΡΠ΅Π΄Π½Π΅Π΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² β 2 (ΠΎΡ 1 Π΄ΠΎ 4 ΠΎΡΠ³Π°Π½ΠΎΠ²).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΠΎΠ»Π½ΡΡ
ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠ΅ΠΉ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π½Π΅ Π±ΡΠ»ΠΎ. Π§Π°ΡΡΠΈΡΠ½Π°Ρ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΡ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° Ρ 26,4% (9/34) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π΄ΠΎΡΡΠΈΠ³Π½ΡΡΠ° Ρ 32,4% (11/34). ΠΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΎ Ρ 41,2% (14/34) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ΅Π΄ΠΈΠ°Π½Π° Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±Π΅Π· ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ΠΎΠΌ ΠΌΠ ΠΠ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 4,09 (95% ΠΠ 2,6β6,53) ΠΌΠ΅ΡΡΡΠ°. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠΉ (3β4 ΡΡΠ΅ΠΏΠ΅Π½ΠΈ) ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡΡ ΡΡΠ°Π»ΠΈ Π½Π΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΡ ΠΈ ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΡ. ΠΠ΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΡ Π±ΡΠ»Π° ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° Ρ 14,7% (5/34), ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΡ ΡΠ°ΠΊΠΆΠ΅ Ρ 14,7% (5/34) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². 5 Π±ΠΎΠ»ΡΠ½ΡΠΌ (14,7%) ΠΏΠΎΡΡΠ΅Π±ΠΎΠ²Π°Π»Π°ΡΡ ΡΠ΅Π΄ΡΠΊΡΠΈΡ Π΄ΠΎΠ·Ρ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½Π° Π² ΡΠ²ΡΠ·ΠΈ Ρ Π½Π΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΠ΅ΠΉ.ΠΡΠ²ΠΎΠ΄Ρ: ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠΉ Π½Π°ΠΌΠΈ Π°Π½Π°Π»ΠΈΠ· Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΠ΅Ρ, ΡΡΠΎ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ Ρ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·ΡΠ΅ΠΌΡΠΌ ΠΈ ΡΠΏΡΠ°Π²Π»ΡΠ΅ΠΌΡΠΌ ΠΏΡΠΎΡΠΈΠ»Π΅ΠΌ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ ΠΠ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΠΏΠΎ Π½Π°ΡΠ΅ΠΌΡ ΠΌΠ½Π΅Π½ΠΈΡ, ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ ΠΌΠΎΠΆΠ΅Ρ ΡΡΠ°ΡΡ Π½ΠΎΠ²ΡΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ ΠΠ
Π€ΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π±ΠΎΠ»ΡΠ½ΠΎΠΉ Ρ Π²ΠΏΡβΠ°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ lsil ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ (ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅)
The article describes a clinical example of timely, safe and effective photodynamic therapy (PDT) in a patient diagnosed with human papillomavirus (HPV) CIN I-associated cervical cancer after ineffective vaccination with 4-valent Gardasil vaccine. Clinical case demonstrates the low effectiveness of HPV vaccination in patients with established HPV infection. In this patient, the lack of adequate treatment for about 1.5 years led to the development of HPV associated CIN I of the cervix. Center for Laser and Photodynamic Diagnostics and Therapy of Tumors and MRI P.A. Herzen, the patient underwent a course of antiviral PDT with the achievement of complete regression of dysplasia and complete eradication of HPV viruses. The patient tolerated the treatment well, without complications. The period of relapse-free follow-up is 19 months.Π ΡΡΠ°ΡΡΠ΅ ΠΎΠΏΠΈΡΡΠ²Π°Π΅ΡΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΈΠΌΠ΅Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΠΉ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (Π€ΠΠ’) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ Ρ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Ρ Π²ΠΈΡΡΡΠΎΠΌ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (ΠΠΠ§) Π‘IN I ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ ΠΏΠΎΡΠ»Π΅ Π½Π΅ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ 4-Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½ΠΎΠΉ Π³Π°ΡΠ΄Π°ΡΠΈΠ». ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΠ΅Ρ Π½ΠΈΠ·ΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΠΠ§ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π½ΠΎΠΉ ΠΠΠ§ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ. Π£ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ ΠΎΠΊΠΎΠ»ΠΎ 1,5 Π»Π΅Ρ ΠΏΡΠΈΠ²Π΅Π»ΠΎ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠΠ§ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ CIN I ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ. Π Π¦Π΅Π½ΡΡΠ΅ Π»Π°Π·Π΅ΡΠ½ΠΎΠΉ ΠΈ ΡΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΈ ΠΠ ΠΠΠΠΠ ΠΈΠΌ. Π.Π. ΠΠ΅ΡΡΠ΅Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ ΠΊΡΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ Π€ΠΠ’ Ρ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎΠ»Π½ΠΎΠΉ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΈ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠΈ ΠΈ ΠΏΠΎΠ»Π½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΊΠ°ΡΠΈΠΈ Π²ΠΈΡΡΡΠΎΠ² ΠΠΠ§. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠ° ΠΏΠ΅ΡΠ΅Π½Π΅ΡΠ»Π° Ρ
ΠΎΡΠΎΡΠΎ, Π±Π΅Π· ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ. Π‘ΡΠΎΠΊ Π±Π΅Π·ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ β 19 ΠΌΠ΅Ρ
Regulation of the CoA Biosynthetic Complex Assembly in Mammalian Cells
Coenzyme A (CoA) is an essential cofactor present in all living cells. Under physiological conditions, CoA mainly functions to generate metabolically active CoA thioesters, which are
indispensable for cellular metabolism, the regulation of gene expression, and the biosynthesis of
neurotransmitters. When cells are exposed to oxidative or metabolic stress, CoA acts as an important
cellular antioxidant that protects protein thiols from overoxidation, and this function is mediated by
protein CoAlation. CoA and its derivatives are strictly maintained at levels controlled by nutrients,
hormones, metabolites, and cellular stresses. Dysregulation of their biosynthesis and homeostasis
has deleterious consequences and has been noted in a range of pathological conditions, including
cancer, diabetes, Reyeβs syndrome, cardiac hypertrophy, and neurodegeneration. The biochemistry
of CoA biosynthesis, which involves five enzymatic steps, has been extensively studied. However,
the existence of a CoA biosynthetic complex and the mode of its regulation in mammalian cells are
unknown. In this study, we report the assembly of all five enzymes that drive CoA biosynthesis,
in HEK293/Pank1Ξ² and A549 cells, using the in situ proximity ligation assay. Furthermore, we
show that the association of CoA biosynthetic enzymes is strongly upregulated in response to serum
starvation and oxidative stress, whereas insulin and growth factor signaling downregulate their
assembly
Raman fingerprints of ultrasmall nanodiamonds produced from adamantane
The synthesis of ultrasmall (2-5 nm) nanodiamonds purely from adamantane at
pressure of 12 GPa is reported. Their structural features have been studied by
Raman spectroscopy. The unusual vibration band containing a number of
pronounced maxima at about 1147, 1245, 1344, and 1456 cm-1 was detected in
Raman spectra. The band is confidently identified with the bending vibrational
modes of CHx groups terminating the nanodiamonds surface. Excessively intense
mode at 1344 cm-1 is explained by its coupling with the 1328 cm-1 diamond
phonons. The Raman band found is proposed to be used for express recognition of
ultrasmall nanodiamonds produced from adamantane and other hydrocarbons with a
high hydrogen content. Moreover, polarized CH bonds on a diamond surface are
sensitive to environmental conditions. This opens up opportunities for using
the diamond produced from adamantane as ultrasmall nanosensors in biology,
chemistry, and medicineComment: 12 pages, 6 figure
- β¦